Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry in vitro
AbstractImmune escape is the hallmark of carcinogenesis. This widely known mechanism is the overexpression of immune checkpoint ligands, such as programmed cell death protein 1 and programmed death-ligand 1 (PD-1/PD-L1), leading to T cell anergy. Therefore, cancer immunotherapy with specific binding...
Main Authors: | Sirintra Sirivisoot, Chatikorn Boonkrai, Tossapon Wongtangprasert, Tanapati Phakham, Phijitra Muanwein, Trairak Pisitkun, Chenphop Sawangmake, Araya Radtanakatikanon, Anudep Rungsipipat |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Veterinary Quarterly |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/01652176.2023.2240380 |
Similar Items
-
Quantification of pharmacokinetic profiles of a recombinant canine PD-1 fusion protein by validated sandwich ELISA method
by: Jicheng Qiu, et al.
Published: (2022-08-01) -
Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
by: Hiroto Takeuchi, et al.
Published: (2020-06-01) -
Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development
by: Tanapati Phakham, et al.
Published: (2022-10-01) -
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
by: Sho Yoshimoto, et al.
Published: (2023-12-01) -
Post-Chemotherapy Canine Lymphomatous Lymph Node Observations on B-Mode and Strain Elastographic Ultrasound
by: Somchin Sutthigran, et al.
Published: (2024-08-01)